Brokerages Set Evommune, Inc. (NYSE:EVMN) Price Target at $45.71

Evommune, Inc. (NYSE:EVMN) has been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $45.7143.

Several equities research analysts recently commented on the company. Weiss Ratings began coverage on Evommune in a report on Tuesday, February 3rd. They set a “sell (e)” rating on the stock. HC Wainwright increased their price objective on shares of Evommune from $35.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Zacks Research upgraded shares of Evommune to a “hold” rating in a research note on Tuesday, December 2nd. Raymond James Financial initiated coverage on shares of Evommune in a research note on Wednesday, January 7th. They issued a “strong-buy” rating and a $40.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Evommune in a report on Monday, December 1st. They set an “outperform” rating and a $42.00 price target for the company.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in Evommune during the 4th quarter valued at approximately $34,000. The Manufacturers Life Insurance Company purchased a new position in shares of Evommune during the 4th quarter valued at approximately $179,000. State Street Corp acquired a new stake in shares of Evommune during the fourth quarter worth approximately $539,000. TD Asset Management Inc bought a new stake in shares of Evommune in the fourth quarter worth $764,000. Finally, Capricorn Fund Managers Ltd bought a new stake in shares of Evommune in the fourth quarter worth $1,027,000.

Evommune Stock Up 13.3%

Evommune stock opened at $31.60 on Friday. The firm has a market capitalization of $996.03 million and a price-to-earnings ratio of -3.92. The stock has a fifty day simple moving average of $19.31. Evommune has a 52-week low of $13.89 and a 52-week high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.